Given the significant unmet need in obesity management and the weight loss outcomes observed in early trials, there is considerable clinical interest though formal NICE appraisal remains some years away
However, beyond weight gain, obesity involves a series of obesity-related diseases, which in patients with PWS can have a stronger impact, considering the early onset of obesity, the difficulties in adhering to lifestyle changes, use of psychotropic medications, and the inability to communicate some symptoms linked to mental retardation [24, 28]
Optimal weight loss results are typically observed over six months to a year, especially when combined with a reduced-calorie diet and regular physical activity
While waiting for potential FDA approval, focus on working with healthcare providers to explore currently available options
The Gln variant has been well characterized as a partial loss-of-function mutation 27,28